PPARG and Insulin resistance: Recently, some sort of ARBs such as telmisartan and to a lesser extent irbesartan partially activate PPAR-γ and effectively treat insulin resistance and dyslipidemia without the toxicity sometimes associated with full PPAR-γ agonists [141, 142].